NKGen Biotech(US:NKGN) Globenewswireยท2025-10-09 12:05Core Viewpoint - NKGen Biotech, Inc. is addressing shareholder concerns regarding its stock price display of $0.00 on certain financial websites, clarifying that this does not reflect the company's actual value but is due to trading on the OTC Expert Market [1][2][4]. Company Status - The $0.00 stock price is a result of limitations on public quote dissemination for securities traded on the OTC Expert Market, not indicative of any changes in the company's fundamentals or operations [2][4]. - NKGen Biotech's common stock is not delisted and remains tradable, although current financial information is restricted to brokers and market makers [5]. Compliance and Reporting - The company is actively working to regain compliance with reporting obligations under the Securities Exchange Act, having filed its Form 10-K for the year ended December 31, 2024, and is focused on completing its Form 10-Qs for the first three quarters of 2025 [6]. - NKGen Biotech is committed to transparency and corporate compliance, with plans to restore full access to market information for shareholders [7]. Company Overview - NKGen Biotech is a clinical-stage biotechnology company specializing in the development and commercialization of innovative autologous and allogeneic natural killer cell therapeutics, headquartered in Santa Ana, California [8].